NL-OMON35491已完成不适用
The effect of interferon beta-1a treatment on functional adaptation in Multiple Sclerosis (MS) - Interferon beta-1a and functional adaptation
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 22
研究概览
简要总结
Trial ended prematurely
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •RRMS or relapsing SPMS
- •Meet safety criteria for MRI
- •Group 1: Subjects affected by RRMS starting or recently started with Interferon beta-1a treatment
- •Group 2: Subjects affected by relapsing SPMS on interferon beta-1a treatment.
- •Group 3: Untreated Subjects affected by RRMS or relapsing SPMS
- •Group 4: Healthy controls
排除标准
- •MS other than RRMS or relapsing SPMS
- •presence or history of psychiatric disease
- •presence or history of neurological disease
- •presence or history of alcohol or drug abuse
- •presence of contra-indications for MRI
- •presence of contra-indications for Rebif
- •Use of immunosupressive agents
研究者
相似试验
进行中（未招募）
不适用
The effect of interferon beta-1a treatment on adaptability of the brain in patients with MSMultiple sclerosisMedDRA version: 14.0Level: PTClassification code 10004504Term: Beta interferon therapySystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2011-003570-89-NLVU University Medical Center
招募中
3 期
Efficacy and safety of Interferon beta-1-a in mild to moderate COVID-19IRCT20120703010178N25Shahid Beheshti University of Medical Sciences100
招募中
3 期
ReciGen for treatment of Covid-19Covid 19.COVID-19, virus identifiedU07.1IRCT20150914024017N1Tehran University of Medical Sciences40
已完成
不适用
Biomarker-based Early Anti-inflammatory Therapy for severe COVID-19Coronavirus infectionCOVID-191004743810024970NL-OMON55200eids Universitair Medisch Centrum275
已完成
2 期
Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative ColitisUlcerative ColitisNCT00303381EMD Serono194